Current stock page

Catalysts

REGN Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 4, 2026

REGN

Catalysts
Regeneron Pharmaceuticals, Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 8/10
Relative Leader / Watch
Strong Relative Position
Score data as of Sep 4, 2026
Last price
$827.72
-$15.75 (-1.87%)
Latest market quote
Momentum55
Value48
Quality73
Risk Resilience62
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Oct 28, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 59/100

Momentum 55/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 14.02%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 55/100AIQ Edge 8/10 Strong Relative Position
Beat rate
88%
7 of 8 reported periods
Average surprise
+17.3%
Across covered historical reports
Latest result
+40.6%
Jul 30, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Jul 30, 2026$10.16$14.29+40.6%$3.82B$4.29B
Apr 29, 2026$8.91$9.47+6.3%$3.48B$3.61B
Jan 30, 2026$10.74$11.44+6.5%$3.81B$3.88B
Oct 28, 2025$9.65$11.83+22.6%$3.59B$3.75B
Aug 1, 2025$8.43$12.89+52.9%$3.29B$3.68B
Apr 29, 2025$8.62$8.22-4.6%$3.25B$3.03B
Feb 4, 2025$11.21$12.07+7.7%$3.74B$3.79B
Oct 31, 2024$11.69$12.46+6.6%$3.67B$3.72B

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
18
Buy
9
Hold
1
Sell
12-month analyst target
$817.52
-1.23% versus current price
Based on 17 analyst observations. Targets are estimates, not predictions.
Low target
$641.00
-22.56% vs latest price
Average target
$817.52
-1.23% vs latest price
High target
$1,030.00
+24.44% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateOct 28, 2026

Next known earnings or reporting date.

EPS estimate$16.04

Current analyst expectation for the upcoming report.

Revenue estimate$4.55B

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score55

Where event reaction would show up first.

AIQ score59/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
17
Average target
$817.52
Target upside
-1.23%
Target range
$641.00 - $1,030.00
90-day revisions
14

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
1
markets.businessinsider.com · Sep 5, 2026

SEPTEMBER 14, 2026 REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

San Diego, California--(Newsfile Corp. - September 5, 2026) - The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or ac...

insidermonkey.com · Aug 27, 2026

Can Regeneron (REGN)’s Rare-Disease Win Move the Earnings Needle?

The FDA approved Pasatru, whose generic name is garetosmab, of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) for adults with fibrodysplasia ossificans progressiva.

finance.yahoo.com · Aug 27, 2026

Regeneron Pharmaceuticals (REGN) Adjusts Course Amid Mixed Results in Melanoma Drug Trials

Sound Shore Management, an investment management firm, has released its investor letter for the second quarter of 2026. The letter can be downloaded here. The Sound Shore Fund’s Investor Class (SSHFX) and Institutional Class (SSHVX) rose 10.48% and 10.58% in the second quarter of 2026, trailing the Russell 1000 Value Index’s 13.87% and the S&P 500’s […]

finance.yahoo.com · Aug 26, 2026

Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?

Regeneron Pharmaceuticals has comfortably outperformed the S&P 500 over the past year, and Wall Street remains reasonably bullish on the company’s long-term growth prospects.

manilatimes.net · Aug 19, 2026

Regeneron Announces Investor Conference Presentations

TARRYTOWN, N.Y., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management participation as follows:

Open full news and sentiment

REGN Catalysts FAQ

What are the next catalysts for REGN stock?

REGN's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move REGN stock?

Upcoming events that could move REGN include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could REGN's next earnings report affect the stock?

REGN's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive REGN stock higher?

REGN could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt REGN stock?

REGN could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.